| Literature DB >> 35289756 |
Matilda Cederberg1,2, Sara Alsén1,2, Lilas Ali1,2,3, Inger Ekman1,2,4, Kristina Glise5, Ingibjörg H Jonsdottir5,6, Hanna Gyllensten1,2, Karl Swedberg1,2,4,7, Andreas Fors1,2,8.
Abstract
BACKGROUND: Sick leave due to common mental disorders (CMDs) is a public health problem in several countries, including Sweden. Given that symptom relief does not necessarily correspond to return to work, health care interventions focusing on factors that have proven important to influence the return to work process, such as self-efficacy, are warranted. Self-efficacy is also a central concept in person-centered care.Entities:
Keywords: anxiety; depression; intervention; mHealth; mobile phone; patient-centered care; person-centered care; randomized controlled trial; sickness absence; stress; telehealth
Year: 2022 PMID: 35289756 PMCID: PMC8965681 DOI: 10.2196/30966
Source DB: PubMed Journal: JMIR Ment Health ISSN: 2368-7959
Figure 1CONSORT (Consolidated Standards of Reporting Trials) diagram. ITT: intention-to-treat; PCC: person-centered care; PP: per-protocol.
Baseline characteristics (N=209).
| Characteristics | Control group (n=107) | Intervention group (n=102) | Per-protocol analysis (n=85) | ||||
| Age (years), mean (SD) | 42.2 (11.7) | 42.3 (11.2) | 42.7 (11.1) | ||||
| Women, n (%) | 93 (87.7)a | 82 (80.4) | 70 (82.4) | ||||
| General self-efficacy score, mean (SD) | 25.9 (6.1) | 25.8 (6.4) | 25.9 (6.0) | ||||
|
| |||||||
|
| Living alone | 30 (28) | 40 (39.2) | 32 (37.6) | |||
|
| Married or living with a partner | 77 (72) | 62 (60.8) | 53 (62.4) | |||
|
| |||||||
|
| Sweden | 91 (85) | 89 (87.3) | 73 (85.9) | |||
|
| Other | 16 (15) | 13 (12.7) | 12 (14.1) | |||
|
| |||||||
|
| Compulsory | 7 (6.6) | 6 (5.9) | 4 (4.7) | |||
|
| Secondary school | 16 (15.1) | 21 (20.8) | 17 (20) | |||
|
| Vocational college | 20 (18.9) | 15 (14.9) | 11 (12.9) | |||
|
| University | 63 (59.4) | 59 (58.4) | 53 (62.4) | |||
|
| |||||||
|
| 0 | 4 (3.7) | 2 (2) | 2 (2.4) | |||
|
| 25 | 3 (2.8) | 5 (4.9) | 4 (4.7) | |||
|
| 50 | 21 (19.6) | 30 (29.4) | 25 (29.4) | |||
|
| 75 | 3 (2.8) | 5 (4.9) | 4 (4.7) | |||
|
| 100 | 76 (71) | 60 (58.8) | 50 (58.8) | |||
|
| |||||||
|
| Stress (F43) | 69 (64.5) | 65 (63.7) | 55 (64.7) | |||
|
| Depression (F32 and F33) | 23 (21.5) | 21 (20.6) | 18 (21.2) | |||
|
| Anxiety (F41) | 15 (14) | 16 (15.7) | 12 (14.1) | |||
|
| |||||||
|
| Previous stress | 29 (27.4)a | 34 (33.3) | 28 (32.9) | |||
|
| Previous depression | 28 (26.4)a | 30 (29.4) | 24 (28.2) | |||
|
| Previous anxiety | 33 (31.1)a | 29 (28.4) | 25 (29.4) | |||
|
| Previous sleep disorder | 15 (14) | 17 (16.7) | 15 (17.6) | |||
|
| |||||||
|
| Antidepressant | 54 (50.5) | 43 (42.2) | 37 (43.5) | |||
|
| Sedative | 49 (46.2)a | 37 (36.3) | 29 (34.1) | |||
|
| Sleep medication | 26 (24.5)a | 25 (24.5) | 19 (22.4) | |||
aOne value missing.
bTwo values missing.
cICD: International Statistical Classification of Diseases and Related Health Problems.
Composite scores at the 3- and 6-month follow-ups (N=209).
|
| Control (n=107), n (%) | Intervention (n=102), n (%) | Odds ratio (95% CI) | Per-protocol analysis (n=85), n (%) | Odds ratio (95% CI) | ||||||||||||||||
|
| |||||||||||||||||||||
|
|
| 2.37 (1.048-5.340) | .04 |
| 2.61 (1.133-5.996) | .02 | |||||||||||||||
|
|
| Improved | 10 (9.3) | 20 (19.6) |
|
| 18 (21.2) |
|
| ||||||||||||
|
|
| Deteriorated or unchanged | 97 (90.7) | 82 (80.4) |
|
| 67 (78.8) |
|
| ||||||||||||
|
|
| .04 |
|
| .009 | ||||||||||||||||
|
|
| Improved | 10 (10) | 20 (20.8) |
|
| 18 (22) |
|
| ||||||||||||
|
|
| Unchanged | 76 (76) | 67 (79.8) |
|
| 59 (72) |
|
| ||||||||||||
|
|
| Deteriorated | 14 (14) | 9 (9.4) |
|
| 5 (6.1) |
|
| ||||||||||||
|
| |||||||||||||||||||||
|
|
| 1.47 (0.795-2.730) | .22 |
| 1.82 (0.968-3.429) | .06 | |||||||||||||||
|
|
| Improved | 25 (23.4) | 31 (31) |
|
| 30 (35.7) |
|
| ||||||||||||
|
|
| Deteriorated or unchanged | 82 (76.6) | 69 (69) |
|
| 54 (64.3) |
|
| ||||||||||||
|
|
| .15 |
|
| .03 | ||||||||||||||||
|
|
| Improved | 25 (24) | 31 (33) |
|
| 30 (37) |
|
| ||||||||||||
|
|
| Unchanged | 64 (61.5) | 53 (56.4) |
|
| 45 (55.6) |
|
| ||||||||||||
|
|
| Deteriorated | 15 (14.4) | 10 (10.6) |
|
| 6 (7.4) |
|
| ||||||||||||
aSeven missing values in the control group, 6 missing values in the intervention group in the intention-to-treat analysis, and 3 missing values in the intervention group in the per-protocol analysis.
bTwo missing values in the intervention group in the intention-to-treat analysis, and 1 missing value in the intervention group in the per-protocol analysis.
cThree missing values in the control group, 8 missing values in the intervention group in the intention-to-treat analysis, and 4 missing values in the intervention group in the per-protocol analysis.
Change in general self-efficacy (GSE) score from baseline to 3- and 6-month follow-ups (N=209).
|
| Control (n=107) | Intervention (n=102) | Odds ratio (95% CI) | Per-protocol analysis (n=85) | Odds ratio (95% CI) | ||||||||||
|
| |||||||||||||||
|
| Change in GSE score, mean (SD) | –0.038 (5.2)a | 2.069 (5.9)b | N/Ac | .03 | 2.557 (5.4)d | N/A | .01 | |||||||
|
| Increase by ≥5 points, n (%) | 11 (10.3) | 23 (22.5) | 2.54 (1.167-5.530) | .02 | 21 (24.7) | 2.86 (1.293-6.342) | .01 | |||||||
|
| |||||||||||||||
|
| Change in GSE score, mean (SD) | 1.380 (5.9)a | 3.204 (6.6)b | N/A | .07 | 3.463 (6.6)d | N/A | .04 | |||||||
|
| Increase by ≥5 points, n (%) | 28 (26.2) | 36 (35.3) | 1.54 (0.851-2.782) | .15 | 34 (40) | 1.88 (1.020-3.468) | .04 | |||||||
an=84 at the 3-month follow-up, and n=94 at the 6-month follow-up.
bn=84 at the 3-month follow-up, and n=82 at the 6-month follow-up.
cN/A: not applicable.
dn=75 at the 3- and 6-month follow-ups.
Overview of self-reported sick leave at the 3- and 6-month follow-ups (N=209).
|
| Three months, control (n=107)a, n (%) | Intervention (n=102)b, n (%) | Per-protocol analysis (n=85)c, n (%) | Six months, control (n=107)a, n (%) | Intervention (n=102)b, n (%) | Per-protocol analysis (n=85)c, n (%) | |||||
|
| .85 |
| .76 |
|
| .96 |
| .93 | |||
|
| Decreased | 62 (75) | 65 (77) |
| 58 (77) |
| 82 (85) | 70 (84) |
| 64 (84) |
|
|
| Unchanged | 19 (23) | 16 (19) |
| 15 (20) |
| 11 (12) | 11 (13) |
| 11 (15) |
|
|
| Increased | 2 (2) | 3 (4) |
| 2 (3) |
| 3 (3) | 2 (2) |
| 1 (1) |
|
an=83 at the 3-month follow-up, and n=96 at the 6-month follow-up.
bn=84 at the 3-month follow-up, and n=83 at the 6-month follow-up.
cn=75 at the 3-month follow-up, and n=76 at the 6-month follow-up.